Search Results

ReviR Therapeutics and Asieris Pharmaceuticals, a global biopharmaceutical leader in the discovery, development, and commercialization of innovative drugs for genitourinary tumors and related diseases, announced a milestone was reached today in their ongoing collaboration.

Asieris Pharmaceuticals has announced its set-up of the Women’s Health Business Unit for commercialization.

Asieris Pharmaceuticals released its 2023 Annual Report, revealing impressive outcomes achieved through its specialty pharma strategy, which has facilitated rapid progress in clinical development, early research, and commercialization.

Photocure ASA, the Bladder Cancer Company, announces that its partner Asieris Pharmaceuticals has communicated the Phase III clinical study results for its non-surgical treatment candidate for cervical high-grade squamous intraepithelial lesions Cevira®.

Asieris Pharmaceuticals announced that its product, APL-2301, used for the treatment of Acinetobacter baumannii infections, was approved for Phase I clinical trials in Australia.

Photocure ASA, the Bladder Cancer Company, announces that its partner Asieris Pharmaceuticals communicated that the National Medical Products Administration accepted the new drug application for Hexvix® in China.

Asieris Pharmaceuticals announced the release of Phase III clinical trial data and real-world study data for APL-1706, a bladder cancer diagnosis and management drug, at the 2024 American Society of Clinical Oncology Genitourinary Cancers Symposium in the form of a poster presentation.

Asieris Pharmaceuticals announced the first-time release of interim analysis data for the Phase II clinical trial of oral APL-1202 in combination with the PD-1 inhibitor tislelizumab for neoadjuvant treatment of muscle-invasive bladder cancer.

Photocure ASA announces that its partner Asieris Pharmaceuticals has communicated that the international multicenter Phase III clinical study of Cevira®, the non-surgical treatment in development for cervical high-grade squamous intraepithelial lesions, will be presented for the first time in the form of an oral presentation at the 2024 European Research Organization on Genital Infection and Neoplasia, held March 13-16 in Stockholm, Sweden: